$PRLD
Prelude Therapeutics Inc

2021 Form 10-K Financial Statement

#000156459022010723 Filed on March 17, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $26.96M $4.870M $10.59M
YoY Change 154.55% 290.85% 176.5%
% of Gross Profit
Research & Development $86.78M $14.57M $48.18M
YoY Change 80.12% 64.65% 98.43%
% of Gross Profit
Depreciation & Amortization $915.0K $130.0K $542.0K
YoY Change 68.82% -40.91% 41.88%
% of Gross Profit
Operating Expenses $113.7M $19.45M $58.76M
YoY Change 93.55% 92.67% 142.03%
Operating Profit -$113.7M -$58.76M
YoY Change 93.55% 109.05%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.041M $200.0K $1.834M
YoY Change 11.29% 257.14% 240.26%
Pretax Income -$111.7M -$19.25M -$56.93M
YoY Change 96.2% 91.75% 106.49%
Income Tax
% Of Pretax Income
Net Earnings -$111.7M -$19.25M -$56.93M
YoY Change 96.2% 91.75% 106.49%
Net Earnings / Revenue
Basic Earnings Per Share -$2.43
Diluted Earnings Per Share -$2.426M -$450.1K -$4.562M
COMMON SHARES
Basic Shares Outstanding 46.05M
Diluted Shares Outstanding 46.05M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $291.2M $218.3M $218.3M
YoY Change 33.41% 1055.03%
Cash & Equivalents $31.83M $218.3M $218.3M
Short-Term Investments $259.4M
Other Short-Term Assets $3.882M $2.500M $2.500M
YoY Change 55.28% 92.31%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $295.1M $220.8M $220.8M
YoY Change 33.66% 991.82% 993.07%
LONG-TERM ASSETS
Property, Plant & Equipment $5.636M $2.480M $2.500M
YoY Change 125.44% 56.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.347M $300.0K $300.0K
YoY Change 1349.0%
Total Long-Term Assets $9.983M $2.781M $2.800M
YoY Change 256.54% 68.85% 64.71%
TOTAL ASSETS
Total Short-Term Assets $295.1M $220.8M $220.8M
Total Long-Term Assets $9.983M $2.781M $2.800M
Total Assets $305.1M $223.6M $223.6M
YoY Change 36.45% 922.31% 921.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.840M $3.920M $3.900M
YoY Change 101.03% 98.58% 95.0%
Accrued Expenses $11.27M $7.455M $7.000M
YoY Change 61.06% 186.4% 204.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $19.20M $11.38M $11.40M
YoY Change 68.43% 135.26% 137.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $32.00K $0.00
YoY Change 540.0%
Total Long-Term Liabilities $0.00 $32.00K $0.00
YoY Change 540.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.20M $11.38M $11.40M
Total Long-Term Liabilities $0.00 $32.00K $0.00
Total Liabilities $19.20M $11.41M $11.40M
YoY Change 68.43% 135.68% 137.5%
SHAREHOLDERS EQUITY
Retained Earnings -$107.4M
YoY Change 112.74%
Common Stock $319.6M
YoY Change 29356.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $285.9M $212.2M $212.2M
YoY Change
Total Liabilities & Shareholders Equity $305.1M $223.6M $223.6M
YoY Change 36.45% 922.31% 921.0%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$111.7M -$19.25M -$56.93M
YoY Change 96.2% 91.75% 106.49%
Depreciation, Depletion And Amortization $915.0K $130.0K $542.0K
YoY Change 68.82% -40.91% 41.88%
Cash From Operating Activities -$83.53M -$14.85M -$46.18M
YoY Change 80.89% 5.32% 79.92%
INVESTING ACTIVITIES
Capital Expenditures -$2.323M -$330.0K $621.0K
YoY Change -474.07% -48.44% -20.38%
Acquisitions
YoY Change
Other Investing Activities -$261.5M
YoY Change
Cash From Investing Activities -$263.8M -$330.0K -$621.0K
YoY Change 42380.35% -48.44% -20.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $161.4M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 164.9M -1.310M 246.2M
YoY Change -33.03% 991.67% 728.24%
NET CHANGE
Cash From Operating Activities -83.53M -14.85M -46.18M
Cash From Investing Activities -263.8M -330.0K -621.0K
Cash From Financing Activities 164.9M -1.310M 246.2M
Net Change In Cash -182.4M -16.49M 199.4M
YoY Change -191.48% 10.97% 5972.78%
FREE CASH FLOW
Cash From Operating Activities -$83.53M -$14.85M -$46.18M
Capital Expenditures -$2.323M -$330.0K $621.0K
Free Cash Flow -$81.21M -$14.52M -$46.80M
YoY Change 73.53% 7.88% 76.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M1D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M28D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y14D
CY2021Q2 dei Entity Public Float
EntityPublicFloat
343300000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
161412000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
319605000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-711000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107426000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
212183000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
223590000
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31828000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
218309000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
259405000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3882000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2500000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
295115000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
220809000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
4044000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3929000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2480000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1707000
CY2021Q4 us-gaap Other Assets
OtherAssets
303000
CY2020Q4 us-gaap Other Assets
OtherAssets
301000
CY2021Q4 us-gaap Assets
Assets
305098000
CY2020Q4 us-gaap Assets
Assets
223590000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7840000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3920000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9621000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7455000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1740000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19201000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11375000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
32000
CY2021Q4 us-gaap Liabilities
Liabilities
19201000
CY2020Q4 us-gaap Liabilities
Liabilities
11407000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
505723000
CY2020 us-gaap Operating Expenses
OperatingExpenses
58763000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
272000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.56
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12478463
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-56929000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-711000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56929000
CY2021 prld Payments Of Offering Costs
PaymentsOfOfferingCosts
739000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-711000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-111694000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-49412000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
100000
CY2020 prld Temporary Equity Stock Converted During Period Value
TemporaryEquityStockConvertedDuringPeriodValue
146211000
CY2020 prld Payments Of Offering Costs
PaymentsOfOfferingCosts
2538000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
166630000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5583000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-56929000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
212183000
CY2021 us-gaap Profit Loss
ProfitLoss
-111694000
CY2020 us-gaap Profit Loss
ProfitLoss
-56929000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
915000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
542000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1328000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-11000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
20931000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1364000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
261480000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
621000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-621000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161424000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
166630000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
303000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
12000
CY2020 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
258000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3504000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
272000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
164897000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
246228000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-182437000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
199430000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
218309000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18879000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35872000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
218309000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
567000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
806000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
765000
CY2021 prld Unrealized Gain Loss On Marketable Securities
UnrealizedGainLossOnMarketableSecurities
-711000
CY2020 prld Offering Costs In Accrued Expenses
OfferingCostsInAccruedExpenses
265000
CY2020 prld Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
24000
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Operations</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.57%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prelude Therapeutics Incorporated (the “Company”) was incorporated in Delaware on February 5, 2016 and is a clinical-stage fully integrated oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients. Since beginning operations, the Company has devoted substantially all its efforts to research and development, conducting preclinical and clinical studies, recruiting management and technical staff, administration, and raising capital.</p>
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-219100000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.56%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.56%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.56%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. The most significant estimate relates to accrued clinical trial expenses.</p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.56%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.56%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships.</p>
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
4044000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31828000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
218309000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35872000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
218309000
CY2021 us-gaap Property Plant And Equipment Depreciation Methods
PropertyPlantAndEquipmentDepreciationMethods
Depreciation expense is recognized using the straight-line method over the estimated useful life of the asset, ranging from 5-7 years
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4919000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3614000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7811090
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8053858
CY2021Q4 prld Offset Accrued Expense And Other Current Liabilities To Eliminate Deferred Rent
OffsetAccruedExpenseAndOtherCurrentLiabilitiesToEliminateDeferredRent
64000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
260116000
CY2021Q4 prld Available For Sale Debt Securities Accumulated Gross Unrealized Gain Net Of Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainNetOfTax
2000
CY2021 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
This option to extend was not recognized as part of the Company’s measurement of the right-of-use asset and operating lease liability as of December 31, 2021
CY2021 prld Operating Lease Estimated Incremental Borrowing Rate Percent
OperatingLeaseEstimatedIncrementalBorrowingRatePercent
0.100
CY2021Q4 prld Available For Sale Debt Securities Accumulated Gross Unrealized Loss Net Of Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossNetOfTax
713000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
259405000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
25
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
221800000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5927000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3563000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1998000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1083000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3929000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2480000
CY2021Q4 prld Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
4615000
CY2020Q4 prld Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
3421000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
87000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
420000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9621000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7455000
CY2021 prld Non Cancellable Lease Period
NonCancellableLeasePeriod
P12M
CY2021 prld Lease Commencement Date
LeaseCommencementDate
2021-07-01
CY2021 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-06-30
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000
CY2021 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
500000
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
13200000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2021 prld Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.35
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.99
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.37
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.46
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2600231
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
31.14
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
995950
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.52
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1263890
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
19.79
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7179482
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.36
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2057975
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.99
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
25100000
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
7179482
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
2057975
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
17500000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.077
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.065
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.035
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.012
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.058
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.044
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.380
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.307
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Tax Credit Carryforward Description
TaxCreditCarryforwardDescription
The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions.
CY2021Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0
CY2021 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
60495000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
28283000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
11240000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4753000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2448000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
33000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1290000
CY2021Q4 prld Deferred Tax Assets Tax Deferred Expense Lease Liabilities
DeferredTaxAssetsTaxDeferredExpenseLeaseLiabilities
485000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
75958000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33069000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
75371000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32899000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
587000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
170000
CY2021Q4 prld Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
476000
CY2021Q4 prld Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
111000
CY2020Q4 prld Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
170000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
587000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
170000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
42500000

Files In Submission

Name View Source Status
0001564590-22-010723-index-headers.html Edgar Link pending
0001564590-22-010723-index.html Edgar Link pending
0001564590-22-010723.txt Edgar Link pending
0001564590-22-010723-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gfbahr30hf0e000001.jpg Edgar Link pending
gfbahr30hf0e000002.jpg Edgar Link pending
gfbahr30hf0e000003.jpg Edgar Link pending
gfbahr30hf0e000004.jpg Edgar Link pending
gfbahr30hf0e000005.jpg Edgar Link pending
gfbahr30hf0e000006.jpg Edgar Link pending
gfbahr30hf0e000007.jpg Edgar Link pending
gfbahr30hf0e000008.jpg Edgar Link pending
gfbahr30hf0e000009.jpg Edgar Link pending
gfbahr30hf0e000010.jpg Edgar Link pending
gfbahr30hf0e000011.jpg Edgar Link pending
gfbahr30hf0e000012.jpg Edgar Link pending
gxrqpuupcgir000001.jpg Edgar Link pending
gxrqpuupcgir000002.jpg Edgar Link pending
gxrqpuupcgir000003.jpg Edgar Link pending
gxrqpuupcgir000004.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
prld-10k_20211231.htm Edgar Link pending
prld-10k_20211231_htm.xml Edgar Link completed
prld-20211231.xsd Edgar Link pending
prld-20211231_cal.xml Edgar Link unprocessable
prld-20211231_def.xml Edgar Link unprocessable
prld-20211231_lab.xml Edgar Link unprocessable
prld-20211231_pre.xml Edgar Link unprocessable
prld-ex1010_340.htm Edgar Link pending
prld-ex1011_220.htm Edgar Link pending
prld-ex1012_710.htm Edgar Link pending
prld-ex107_338.htm Edgar Link pending
prld-ex108_339.htm Edgar Link pending
prld-ex109_521.htm Edgar Link pending
prld-ex231_10.htm Edgar Link pending
prld-ex311_6.htm Edgar Link pending
prld-ex312_9.htm Edgar Link pending
prld-ex321_7.htm Edgar Link pending
prld-ex322_8.htm Edgar Link pending
prld-ex44_11.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending